Leuprolide

Mechanism of Action

Leuprolide is a synthetic nonapeptide analog of GnRH that exhibits biphasic endocrine effects. Initial administration triggers a transient surge of pituitary luteinizing hormone and follicle-stimulating hormone, leading to increased gonadal steroid production (estrogen in females and testosterone or dihydrotestosterone in males) that lasts from days to weeks. Continued exposure achieved through long-acting depot formulations results in sustained receptor stimulation, paradoxical downregulation and desensitization of pituitary GnRH receptors, and reversible selective suppression of the hypothalamic-pituitary-gonadal axis. This mechanism underlies the broad therapeutic utility of leuprolide across oncologic and reproductive disorders. For example, castrate levels of testosterone induce apoptosis of androgen-dependent prostate cancer cells, whereas suppression of estrogen secretion and angiogenesis alleviates endometriosis-related pain and lesion activity.[25]

Pharmacokinetics (Lupron Depot Formulation)

Absorption: Bioavailability after subcutaneous (SC) administration is comparable with that after intravenous (IV) administration. 

Distribution: The mean steady-state volume of distribution (Vd): 27 L following IV bolus in healthy male volunteers. Protein binding is 43% to 49% in vitro in human plasma.

Metabolism: Leuprolide is primarily degraded by peptidases into inactive peptide fragments. Metabolites include pentapeptide (Metabolite I), tripeptides (Metabolites II and III), and a dipeptide (Metabolite IV). The major metabolite (M-I) reaches peak concentrations at 2 to 6 hours and represents approximately 6% of peak parent drug levels. At 1 week, mean plasma M-I concentrations are approximately 20% of mean leuprolide concentrations.

Elimination: The mean systemic clearance is 7.6 L/h following IV administration. The terminal elimination half-life is approximately 3 hours based on a 2-compartment model. Less than 5% of the administered dose is recovered in urine as the parent drug and the M-I metabolite.

Administration

Available Dosage Forms and Strengths

Since its first FDA approval in 1985 as a daily intramuscular (IM) or SC injection, leuprolide has evolved into numerous long-acting depot formulations that improve patient accessibility, quality of life, and treatment adherence. Depot formulations use distinct biodegradable poly(lactic-co-glycolic acid) (PLGA) matrices to achieve extended release. Because each strength exhibits specific release characteristics, formulations should not be interchanged, combined, or fractionated to achieve a desired dose.

Table. Leuprolide Formulations With Characteristics, Routes of Administration, and Strengths

Abbreviations: ATRIGEL, Atrigel delivery system; CPP, central precocious puberty; IM, intramuscular; SC, subcutaneous

Adult Dosage

Patients may receive injections at 1-, 3-, 4-, or 6-month intervals depending on the indication and clinical requirements. FDA-approved depot formulations include doses ranging from 7.5 mg monthly up to 45 mg every 6 months for prostate cancer, 3.75 mg monthly for endometriosis or fibroids, and 45 mg every 6 months for CPP.

Treatment of advanced prostate cancer

Lutrate Depot is administered as 22.5 mg intramuscularly every 12 weeks (3 months) as a single injection.

Lupron Depot, Eligard, and Vabrinty are indicated in the following dosages, with route of administration varying by product (refer to individual prescribing information):

• 7.5 mg every month 
• 22.5 mg every 3 months
• 30 mg every 4 months
• 45 mg every 6 months

Camcevi is administered at a dosage of 42 mg subcutaneously every 6 months.

Treatment of central precocious puberty

Fensolvi is indicated for the treatment of pediatric patients aged 2 years and older with CPP. Fensolvi is administered as a 45 mg dose via SC injection every 6 months. 

Specific Patient Populations

Renal impairment: Dose adjustment is generally not required for renal impairment or hemodialysis because less than 5% of the drug is eliminated in the urine and it is not significantly dialyzed.[26][27]

Hepatic impairment: The pharmacokinetics of leuprolide have not been studied in patients with hepatic impairment.

Pregnancy considerations: Leuprolide use is contraindicated during pregnancy. Females and males of reproductive potential should be informed of the potential for impaired fertility, and patients should be counseled on pregnancy planning and prevention. 

Breastfeeding considerations: Information regarding the presence of leuprolide acetate in human or animal milk is currently unavailable. No data are available to assess the potential effects of leuprolide acetate on breastfed infants or its influence on lactation and milk production.

Pediatric considerations: Safety and effectiveness in pediatric patients have been established only for Lupron Depot-Ped and Fensolvi. Use is contraindicated for other formulations, including Lupron Depot, Lutrate, Vabrinty, Eligard, and Camcevi.

Adverse Effects

In adults, adverse effects vary in frequency across formulations and indications. The most common adverse effects include hot flashes, fatigue, gastrointestinal upset, headache, depression, severe cutaneous adverse reactions, infection, arthralgia, hypertension, decreased libido, vaginitis, impotence, and testicular atrophy. Important considerations for counseling and prescribing include worsening or new-onset symptoms in the first few weeks of treatment, metabolic syndrome, bone mineral density loss, cardiovascular events, and potential QT interval prolongation, convulsions, or embryo-fetal toxicity. Less commonly, patients may develop weight gain, dizziness, myalgia, alopecia, or pituitary apoplexy.[19][20]

Lupron Depot 7.5 mg (1-month formulation): Adverse reactions occurring in more than 10% of patients included generalized pain, vasomotor symptoms (hot flashes and sweating), edema, gastrointestinal, respiratory, and urinary disorders.

Lupron Depot 22.5 mg (3-month formulation): Frequently reported adverse effects (>10%) included generalized pain, injection site reactions, hot flashes and sweating, joint disorders, gastrointestinal symptoms, urinary disorders, and testicular atrophy. 

Lupron Depot 30 mg (4-month formulation): Common adverse reactions (>10%) included asthenia, influenza-like symptoms, generalized pain, headache, injection site reactions, vasomotor symptoms (hot flashes and sweating), gastrointestinal disturbances, edema, cutaneous reactions, and urinary disorders.

Lupron Depot 45 mg (6-month formulation): The most frequently observed adverse events (>10%) included hot flushes, injection site pain, upper respiratory tract infections, and fatigue.

Postmarketing experience: Additional adverse events reported during postmarketing surveillance included mood changes, depression, rare instances of suicidal ideation and attempts, pituitary apoplexy, and infrequent cases of severe drug-induced liver injury.[28]

Lupron Depot-Ped 45 mg (6-month formulation): In clinical studies, adverse reactions reported in 4% or more of patients included injection site reactions, headache, psychiatric disorders, diarrhea, abdominal pain, bleeding events,  fever, nausea and vomiting, pruritus, pain in the extremities, rash, back pain, ligament sprain, weight gain, fractures, breast tenderness, insomnia, chest pain, and excessive sweating. Because the adverse reaction profile may vary across formulations and dosing regimens of leuprolide, clinicians should refer to the respective product labeling for detailed, formulation-specific safety information.[29]

Contraindications

Leuprolide is contraindicated in patients with known hypersensitivity to GnRH, GnRH agonists, or any component of the formulation. Leuprolide is also contraindicated during pregnancy and should not be used during breastfeeding due to an increased risk of pregnancy loss, potential for embryo-fetal toxicity, and absence of safety data. Although leuprolide typically inhibits ovulation and induces amenorrhea, pregnancy may still occur. A negative pregnancy test should be confirmed before initiating therapy in patients of reproductive potential, and non-hormonal contraception should be used during treatment. Use in patients with undiagnosed abnormal uterine bleeding is contraindicated until malignancy or other causes have been excluded.

No clinically significant drug-drug interactions have been identified; however, clinicians should exercise caution when prescribing leuprolide to patients with a history of or risk factors for osteoporosis, cardiovascular disease, QT interval prolongation, or seizure disorders.

Warning and Precautions

Tumor flare: Initiation of therapy with Lupron Depot may cause a transient increase in serum testosterone levels, potentially rising to approximately 50% above baseline. Patients should be closely monitored during the initial weeks for any worsening of prostate cancer–related symptoms. Particular attention should be given to the development or progression of bone pain, hematuria, neuropathy, ureteral obstruction, and signs of spinal cord compression, which can lead to paralysis and, in severe cases, life-threatening complications.

Metabolic effects: Treatment with GnRH agonists has been associated with metabolic disturbances, including hyperglycemia, diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease. Patients should be monitored for features of metabolic syndrome, including lipid profiles and glycemic parameters (eg, blood glucose and HbA1c), and management should be guided by current clinical recommendations.

Cardiovascular risk: Use of GnRH analogs in men has been linked to an increased risk of cardiovascular events, including myocardial infarction, sudden cardiac death, and stroke. Ongoing assessment of cardiovascular risk is recommended, with appropriate management in accordance with standard clinical practice. ADT may be associated with QT interval prolongation, and the potential risks and benefits should be carefully evaluated.

Convulsions: Seizure activity has been reported in patients receiving therapy, both in those with and without identifiable risk factors. Clinicians should institute appropriate management in accordance with standard guidelines.

Severe cutaneous adverse reactions: Serious skin reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis, have been reported. Treatment should be discontinued if symptoms suggestive of such reactions arise and permanently stopped if the diagnosis is confirmed.

Monitoring

Monitoring should be tailored to the indication and the patient's risk profile. Additionally, little consensus exists regarding the optimal frequency of laboratory investigations. Routine clinical assessments should include evaluation for symptom flare, therapeutic response, and adverse effects. Periodic monitoring of blood pressure, lipid profile, blood glucose levels, and/or HbA1c should be performed due to the risk of metabolic syndrome and cardiovascular events. Echocardiogram and electrolyte testing should also be considered.

In prostate cancer, periodic monitoring of serum testosterone and prostate-specific antigen levels is recommended, particularly if the anticipated clinical or biochemical response to treatment has not been achieved. In the majority of patients receiving leuprolide, testosterone levels initially rise above baseline and then decline to castrate levels (currently defined as <20 ng/dL) within 4 weeks. Clinicians should be aware of the type and precision of the assay methodology used when interpreting results.[1]

In precocious puberty, treatment response should be monitored by assessing ongoing signs and symptoms of pubertal progression and by performing laboratory investigations. These include a GnRH agonist stimulation test, basal serum luteinizing hormone, serum follicle-stimulating hormone, or serum sex steroid levels at 1 to 2 months after initiation of therapy and thereafter as needed to confirm adequate suppression of the hypothalamic-pituitary-gonadal axis and secondary sexual characteristics. Height should be measured every 3 to 6 months, and bone age should be periodically monitored. Medication nonadherence or inadequate dosing may lead to insufficient control of pubertal progression. In cases of inadequate dosing, switching to an alternative GnRH agonist that allows dose adjustment may be considered.

Toxicity

No documented cases of acute leuprolide overdose have been reported, and studies evaluating larger doses have demonstrated good tolerability. However, leuprolide poses a potential risk of embryo-fetal toxicity and is contraindicated in pregnancy. Certain formulations may also contain benzyl alcohol as a preservative, which has been associated with “gasping syndrome” when administered in large amounts (99 mg/kg/day or more). This potentially fatal condition is characterized by central nervous system depression, respiratory distress, metabolic acidosis, and hemodynamic instability.[30]

Enhancing Healthcare Team Outcomes

Safe and effective leuprolide therapy requires a coordinated multidisciplinary approach. Physicians identify suitable candidates, counsel patients regarding the anticipated benefits and potential risks, select evidence-based dosing regimens, and monitor for therapeutic and adverse effects. Pharmacists ensure accurate dispensing, advise on depot-formulation selection, and provide patient education on administration, medication storage, and adverse effect management. Nursing staff play a central role in medication administration, patient education, reinforcement of adherence to therapy, and identification of early signs of adverse effects. Psychologists are key members of the team, providing mental health assessment and support, particularly in addressing symptom flare and the psychosocial effects of early pubertal development and hormonal suppression in precocious puberty. Primary care providers are essential for managing comorbid conditions such as osteoporosis and metabolic syndrome that may be induced or exacerbated by leuprolide therapy.

Effective communication and structured feedback systems within the interprofessional team improve patient safety and outcomes. Pharmacists and nurses facilitate timely intervention by promptly notifying prescribers of concerns regarding therapy appropriateness, patient comprehension, or emerging adverse effects. Multidisciplinary discussions help balance efficacy, safety, cost, and patient preferences when determining the duration or combination of therapy. Accurate documentation promotes continuity of care, minimizes errors, and supports consistency in follow-up. Through collaboration, effective communication, and shared decision-making, the interprofessional healthcare team enhances patient safety, therapeutic outcomes, and quality of life for patients receiving leuprolide at all stages of care.